HeartSciences is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one of the millions of ECG…
November 13, 2024 Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused…
October 14, 2024 Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming…
HeartSciences had a unique opportunity to showcase our MoVista® wavECG™ Technology during the UN General Assembly on Wednesday September 25th. Mark Hilz (COO) also presented the MyoVista wavECG Device as part of…
It was a privilege to represent HeartSciences, Inc. at a prestigious roundtable event, sponsored by the government of Vietnam and leading technology company FPT. This exciting event focused on the…
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs…
